Pemazyre (pemigatinib) is currently under a funding review in Canada for the treatment of locally advanced unresectable or metastatic (stage IV) biliary tract cancer.

Cholangio-Hepatocellular Carcinoma Canada (CHCC) is leading a patient evidence re-submission for this first line targeted treatment of adult patients diagnosed with locally advanced unresectable or metastatic biliary tract cancer and who have the FGFR2 fusion mutation (biomarker).

We are looking for biliary tract cancer patients (or their caregivers) with firsthand experience with this therapy, who are willing to share their valuable story via phone or Zoom. The patient’s perspective will help to inform our patient input submission and provide the expert committees in Canada with this important insight as they prepare to issue their funding recommendation for this drug in Canada.

The patients (or caregivers) who participate in the interview process will have their privacy and confidentiality respected and maintained at all times. Their input will be completely anonymized in the submission. The telephone interview will last approximately 60 minutes and while there is no guarantee, it may help to get this drug funded throughout Canada.

Patients and caregivers may consent to have their contact information (name, phone # and email address) sent to Brenda Clayton, and, in turn, the patient/caregiver will be contacted with an appointment time and date for participation in the telephone interview.

Alternatively, the patient/caregiver may contact Brenda directly ASAP to advise of their willingness to participate in a telephone or Zoom interview to help form the patient input submission to make a meaningful impact:

Brenda Clayton, pemazyre@mychcc.ca; local: 403-701-7017 or toll free: 1-877-694-0314

Please contact Brenda ASAP to schedule the phone interview.